Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight

Summary

Market analysis article discussing the transformation of the Sjögren's syndrome market toward targeted immunomodulatory therapies, highlighting emerging candidates from Vor Biopharma, Amgen, and Johnson & Johnson including Telitacicept, Dazodalibep, and Nipocalimab.